EU IVDR Milestone: Cancer Biomarker Test First To Get A Companion Diagnostic CE Marking
A major milestone has been reached in the EU after a cancer biomarker assay became the first product to receive a companion diagnostic certificate in the context of the EU In Vitro Diagnostic Regulation.
You may also be interested in...
A new Q&A document from the European Medicines Agency outlines the key steps that pharma companies should take when using companion diagnostics in clinical trials, and the information it expects to see in marketing authorization applications.
UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?
The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.